The cyclin-dependent kinase inhibitor p27(Kip1) safeguards against inflammatory injury

Nature Medicine

Volumn 4, Issue 5, 1998, Pages 575-580

  Ophascharoensuk, Vuddhidej ^c   Fero, Matthew L ^a   Hughes, Jeremy ^c   Roberts, James M ^a,b   Shankland, Stuart J ^c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; MITOGENIC AGENT; SCLEROPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; GLOMERULONEPHRITIS; INFLAMMATION; KIDNEY TUBULE EPITHELIUM; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; URETER OBSTRUCTION;

ANIMALS; APOPTOSIS; CDC2-CDC28 KINASES; CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; GLOMERULONEPHRITIS; KIDNEY; KIDNEY FUNCTION TESTS; KIDNEY GLOMERULUS; KIDNEY TUBULES; MICE; MICE, MUTANT STRAINS; MICROTUBULE-ASSOCIATED PROTEINS; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS; URETERAL OBSTRUCTION;

ANIMALIA;

EID: 0031834175     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0598-575     Document Type: Article

References (30)

1. Bisgaard, H.C. & Thorgeirsson, S.S. Hepatic regeneration. The role of regeneration in pathogenesis of chronic liver disease. Clin. Lab. Med. 16, 325-339 (1996).
2. MacLeod, D.C. et al. Proliferation and extracellular matrix synthesis of smooth muscle cells from cultured human coronary atherosclerotic and restenotic lesions. J. Am. Coll. Cardiol. 23, 59-65 (1994).
3. Johnson, R.J. The glomerular response to injury: Progression or resolution? Kidney Int. 45, 1769-1782 (1994).
4. Couser, W.G. & Johnson, R.J. Mechanisms of progressive renal disease in glomerulonephritis. Am. J. Kidney Dis. 23, 193-198 (1994).
5. Morgan, D.O. Principles of CDK regulation. Nature 374, 131-134 (1995).
6. Sherr, C.J. & Roberts, J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes & Dev. 9, 1149-1163 (1995).
7. Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372, 570-573 (1994).
8. Kip1, a cyclin-dependent kinase inhibitor and potential mediator of extracellular antimitogenic signals. Cell 78, 59-66 (1994).
9. Kip1 for restriction point control of the fibroblast cell cycle. Science 272, 877-880 (1996).
10. Kip1. Kidney Int. 51, 1088-1099 (1997).
11. Kip1-deficient mice. Cell 85, 733-744 (1996).
12. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85, 707-720 (1996).
13. Kip1. Cell 85, 721-732(1996).
14. Atkins, R.C., Nikolic-Paterson, D.J., Song, Q. & Lan, H.Y. Modulators of crescentic glomerulonephritis. J. Am. Soc. Nephrol. 7, 2271-2278 (1996).
15. Truong, L.D. et al. Cell apoptosis and proliferation in experimental obstructive uropathy. Kidney Int. 50, 200-207 (1996).
16. Wang, J. & Walsh, K. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science 273, 359-361 (1996).
17. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med. 3, 222-225 (1997).
18. Kip1 protein: Prognostic implications in primary breast cancer. Nature Med. 3, 227-230 (1997).
19. Loda, M. et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med. 3, 231-234 (1997).
20. Salant, D.J., Darby, C. & Couser, W.G. Experimental membranous glomerulonephritis in rats. J. Clin. Invest. 66, 71-81 (1980).
21. Couser, W.G, D.C., Salant, D.J., Adler, S., Stilmant, M.M. & Lowenstein, L.M. Anti-GBM antibody-induced proteinuria in isolated perfused rat kidney. Am. J. Physiol. 249, 241-250 (1985).
22. Butler, A.R. The Jaffe reaction. Identifcation of the colored species. Cli. Chim. Acta. 59, 227-232 (1975).
23. Bradley, C.M. & Benson E.S. Examination of the Urine. (WB Saunders, 1974).
24. Shankland, S.J. et al. Changes in cell cycle protein expression during experimental mesangial proliferative glomerulonephritis. Kidney Int. 50, 1230-1239 (1996).
25. Baker, P.J. et al. Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats. Am. J. Pathol. 135, 185-194 (1989).
26. Shankland, S.J. et al. Cyclin kinase inhibitors are increased during experimental membranous nephropathy: potential role in limiting glomerular epithelial cell proliferation in vivo. Kidney Int. 52, 404-413 (1997).
27. Kerr, P.G, Lan, L.H. & Atkins, R.C. Diseases of The Kidney 6th edn (ed. Schner RW, G.C.) 1619-1 644 (Little, Brown, and Company, 1997).
28. Thomas, S.E. et al. Tubulointerstitial disease in aging: evidence for underlying peritubular capillary damage, a potential role for renal ischemia. J. Am. Soc. Nephrol. 9, 231-242 (1998).
29. Huang, X.R., Tipping, P.G., Li, S. & Holdsworth, S.R. TH1 responsiveness to nephritogenic antigens determines susceptibility to crescentic glomerulonephritis in mice. Kidney Int. 51, 94-103 (1997).
30. Wolf, N.S., Kone, A., Priestley, G.V. & Bartelmez, S.H. In vivo and in vitro characterization of long-term repopulating primitive hematopoietic cells isolated by sequential Hoechst 33342-rhodamine 123 FACS selection. Exp. Hematol. 21, 614-622 (1993).